Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 1, 2013, Pages 32-45

  Tsukie, Noriaki ^a   Nakano, Kaku ^a   Matoba, Tetsuya ^a   Masuda, Seigo ^a   Iwata, Eiko ^a   Miyagawa, Miho ^a   Zhao, Gang ^b   Meng, Wei ^b   Kishimoto, Junji ^a   Sunagawa, Kenji ^a   Egashira, Kensuke ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Drug delivery system; Nanotechnology; Signal transduction; Statin

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CYPHER; FLUINDOSTATIN; GLYCERYL TRINITRATE; IOPAMIDOL; PACLITAXEL; PITAVASTATIN; POLYGLACTIN; PRAVASTATIN; RAPAMYCIN; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOMESTIC PIG; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN-STENT RESTENOSIS; MALE; NONHUMAN; SCANNING ELECTRON MICROSCOPY; SCORING SYSTEM; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CONSTRICTION, PATHOLOGIC; CORONARY ARTERY DISEASE; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; QUINOLINES; SWINE;

EID: 84873861122     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.13862     Document Type: Article

References (35)

1. Laskey WK, Yancy CW, Maisel WH: Thrombosis in coronary drug-eluting stents: Report from the meeting of the circulatory system medical devices advisory panel of the food and drug administration center for devices and radiologic health, december 7-8, 2006. Circulation, 2007; 115: 2352-2357
2. Serruys PW, Kutryk MJ, Ong AT: Coronary-artery stents. N Engl J Med, 2006; 354: 483-495
3. Shuchman M: Trading restenosis for thrombosis? New questions about drug-eluting stents. N Engl J Med, 2006; 355: 1949-1952
4. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R: Drug-eluting stent and coronary thrombosis: Biological mechanisms and clinical implications. Circulation, 2007; 115: 1051-1058
5. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R: Vascular responses to drug eluting stents. Importance of delayed healing. Arterioscler Thromb Vasc Biol, 2007; 27: 1500-1510
6. Finn AV, Joner M, Nakazawa G, Kolodgie F, Newell J, John MC, Gold HK, Virmani R: Pathological correlates of late drug-eluting stent thrombosis: Strut coverage as a marker of endothelialization. Circulation, 2007; 115: 2435-2441
7. Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, Gold HK, Kolodgie FD, Virmani R: Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol, 2008; 52: 333-342
8. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol, 2001; 21: 1712-1719
9. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF: Statin prevents tissue factor expression in human endothelial cells: Role of rho/rho-kinase and akt pathways. Circulation, 2002; 105: 1756-1759
10. Thyberg J: Re-endothelialization via bone marrow-derived progenitor cells: Still another target of statins in vascular disease. Arterioscler Thromb Vasc Biol, 2002; 22: 1509-1511
11. Werner N, Priller J, Laufs U, Endres M, Bohm M, Dirnagl U, Nickenig G: Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: Effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol, 2002; 22: 1567-1572
12. Yokoyama T, Miyauchi K, Kurata T, Satoh H, Daida H: Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis, 2004; 174: 253-259
13. Indolfi C, Cioppa A, Stabile E, Di Lorenzo E, Esposito G, Pisani A, Leccia A, Cavuto L, Stingone AM, Chieffo A, Capozzolo C, Chiariello M: Effects of hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury. J Am Coll Cardiol, 2000; 35: 214-221
14. Scheller B, Schmitt A, Bohm M, Nickenig G: Atorvastatin stent coating does not reduce neointimal proliferation after coronary stenting. Zeitschrift fur Kardiologie, 2003; 92: 1025-1028
15. Miyauchi K, Kasai T, Yokayama T, Aihara K, Kurata T, Kajimoto K, Okazaki S, Ishiyama H, Daida H: Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model. Circ J, 2008; 72: 832-838
16. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, Branzi A, Shepherd J, Suryapranata H, de Feyter PJ, Melkert R, van Es GA, Pfister PJ: A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (flare) trial. Eur Heart J, 1999; 20: 58-69
17. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, Bassand JP, Machecourt J, Cassagnes J, Mossard JM, Vacheron A, Castaigne A, Danchin N, Lablanche JM: Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The predict trial investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol, 1997; 30: 863-869
18. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB, 3rd, Ivanhoe R, Cedarholm JC, Stillabower ME, Talley JD, DeMaio SJ, et al: Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin restenosis trial study group. N Engl J Med, 1994; 331: 1331-1337
19. Onaka H, Hirota Y, Kita Y, Tsuji R, Ishii K, Ishimura T, Kawamura K: The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Jpn Circ J, 1994; 58: 100-106
20. Bae JH, Bassenge E, Kim KY, Synn YC, Park KR, Schwemmer M: Effects of low-dose atorvastatin on vascular responses in patients undergoing percutaneous coronary intervention with stenting. J Cardiovasc Pharmacol Ther, 2004; 9: 185-192
21. Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, Ciabatti N, Mariani M: Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: A randomized study with intravascular ultrasound. Am Heart J, 2005; 149: 520-526
22. Nakano K, Egashira K, Masuda S, Funakoshi K, Zhao G, Kimura S, Matoba T, Sueishi K, Endo Y, Kawashima Y, Hara K, Tsujimoto H, Tominaga R, Sunagawa K: Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC Cardiovasc Interv, 2009; 2: 277-283
23. Kimura S, Egashira K, Nakano K, Iwata E, Miyagawa M, Tsujimoto H, Hara K, Kawashima Y, Tominaga R, Sunagawa K: Local delivery of imatinib mesylate (sti571)- incorporated nanoparticle ex vivo suppresses vein graft neointima formation. Circulation, 2008; 118: S65-70
24. Masuda S, Nakano K, Funakoshi K, Zhao G, Meng W, Kimura S, Matoba T, Miyagawa M, Iwata E, Sunagawa K, Egashira K: Imatinib mesylate-incorporated nanoparticleeluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J Atheroscler Thromb, 2011; 18: 1043-1053
25. Aoki T, Nishimura H, Nakagawa S, Kojima J, Suzuki H, Tamaki T, Wada Y, Yokoo N, Sato F, Kimata H, Kitahara M, Toyoda K, Sakashita M, Saito Y: Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase. Arzneimittel-Forschung, 1997; 47: 904-909
26. Ohtani K, Usui M, Nakano K, Kohjimoto Y, Kitajima S, Hirouchi Y, Li XH, Kitamoto S, Takeshita A, Egashira K: Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys. Gene Ther, 2004; 11: 1273-1282
27. Camici GG, Steffel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K, Matter CM, Yang Z, Luscher TF, Tanner FC: Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: A potential treatment strategy for drug-eluting stents. Circulation, 2006; 114: 1512-1521
28. Egashira K, Nakano K, Ohtani K, Funakoshi K, Zhao G, Ihara Y, Koga J, Kimura S, Tominaga R, Sunagawa K: Local delivery of anti-monocyte chemoattractant protein-1 by gene-eluting stents attenuates in-stent stenosis in rabbits and monkeys. Arterioscler Thromb Vasc Biol, 2007; 27: 2563-2568
29. Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa K, Katoh M, Zhao Q, Kitamoto S, Takeshita A: Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J, 2002; 16: 1838-1840
30. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, Nishida K, Inoue S, Katoh M, Ichiki T, Takeshita A: Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res, 2002; 90: 1167-1172
31. Egashira K: Molecular mechanisms mediating inflammation in vascular disease: Special reference to monocyte chemoattractant protein-1. Hypertension, 2003; 41: 834-841
32. Ohtani K, Egashira K, Nakano K, Zhao G, Funakoshi K, Ihara Y, Kimura S, Tominaga R, Morishita R, Sunagawa K: Stent-based local delivery of nuclear factor-kappab decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation, 2006; 114: 2773-2779
33. van der Giessen WJ, Lincoff AM, Schwartz RS, van Beusekom HM, Serruys PW, Holmes DR Jr, Ellis SG, Topol EJ: Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation, 1996; 94: 1690-1697
34. Lincoff AM, Furst JG, Ellis SG, Tuch RJ, Topol EJ: Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol, 1997; 29: 808-816
35. Schwartz RS, Edelman ER, Carter A, Chronos N, Rogers C, Robinson KA, Waksman R, Weinberger J, Wilensky RL, Jensen DN, Zuckerman BD, Virmani R: Drug-eluting stents in preclinical studies: Recommended evaluation from a consensus group. Circulation, 2002; 106: 1867-1873